Nanobiotix: transfer of NBTXR3 rights in Asia

(CercleFinance.com) - Nanobiotix announces that its partner LianBio has entered into an agreement to transfer to Janssen Pharmaceutica, a subsidiary of Johnson & Johnson, exclusive development and commercialization rights to NBTXR3 in China, South Korea, Singapore and Thailand.


This rights transfer agreement consolidates the worldwide development and commercialization rights to NBTXR3 with Janssen and simplifies the global alliance with Nanobiotix for the co-development and registration of its radioenhancer.

It includes the transfer of previously agreed economic terms, including the right for Nanobiotix to be eligible to receive up to a total of $220 million in potential milestone payments, and tiered double-digit royalties on sales.

Copyright (c) 2023 CercleFinance.com. All rights reserved.